

	¹⁷⁷ Lu-DTPA-sdAb 9077	¹⁷⁷ Lu-DTPA-sdAb 9079	¹⁷⁷ Lu-DTPA-ctrl sdAb
Thymus	0.10 ± 0.02	0.11 ± 0.04	0.14 ± 0.01
Heart	0.15 ± 0.04	0.16 v 0.04	0.21 ± 0.02
Lungs	0.40 ± 0.08	0.34 ± 0.01	0.65 ± 0.10
Liver	0.53 ± 0.18	0.28 ± 0.00	0.60 ± 0.13
Spleen	0.16 ± 0.01	0.20 ± 0.05	0.29 ± 0.02
Pancreas	0.15 ± 0.03	0.13 ± 0.02	0.23 ± 0.08
Kidneys	35.02 ± 0.98	8.58 ± 1.05	60.64 ± 3.85
Stomach	0.30 ± 0.05	0.4 ± 0.24	0.42 ± 0.15
S Intestine	0.38 ± 0.22	0.35 ± 0.06	0.41 ± 0.34
L Intestine	0.21 ± 0.04	0.26 ± 0.10	0.47 ± 0.14
Muscle	0.16 ± 0.04	0.11 ± 0.03	0.16 ± 0.04
Bone	0.14 ± 0.04	0.09 ± 0.01	0.18 ± 0.04
L Nodes	0.48 ± 0.23	0.22 ± 0.02	0.42 ± 0.02
Blood	0.31 ± 0.05	0.26 ± 0.05	0.32 ± 0.02
Tumor	3.72 ± 0.93	3.44 ± 1.31	0.64 ± 0.09
T/M	25.7 ± 13.5	32.9 ± 15.6	4.2 ± 0.7
T/B	11.8 ± 1.1	13.3 ± 4.6	1.9 ± 0.2

Supplemental Table S4. *Ex vivo* biodistribution of ¹⁷⁷Lu-DTPA-sdAb 9077, 9079 and non-target control sdAb (¹⁷⁷Lu-DTPA-ctrl sdAb) at 1.5 h p.i., co-infused with 150 mg/kg Gelofusin, in hCD20 B16 tumor mouse model. Results are presented as mean % IA/g ± SD (n = 3 per sdAb). T/M: Tumor-to-Muscle ratio; T/B: Tumor-to-Blood ratio.